Johan Maertens

1999–2026 年に発表

259
論文数
46,995
被引用数
97
h 指数
244
i10 指数

被引用数

Johan Maertens の年別被引用数1989 年: 被引用 1 件1990 年: 被引用 1 件1994 年: 被引用 1 件1996 年: 被引用 1 件1998 年: 被引用 1 件2000 年: 被引用 4 件2001 年: 被引用 16 件2002 年: 被引用 45 件2003 年: 被引用 66 件2004 年: 被引用 101 件2005 年: 被引用 119 件2006 年: 被引用 158 件2007 年: 被引用 242 件2008 年: 被引用 274 件2009 年: 被引用 235 件2010 年: 被引用 316 件2011 年: 被引用 315 件2012 年: 被引用 298 件2013 年: 被引用 226 件2014 年: 被引用 307 件2015 年: 被引用 289 件2016 年: 被引用 351 件2017 年: 被引用 258 件2018 年: 被引用 307 件2019 年: 被引用 1,282 件2020 年: 被引用 1,452 件2021 年: 被引用 1,610 件2022 年: 被引用 1,214 件2023 年: 被引用 1,061 件2024 年: 被引用 1,723 件2025 年: 被引用 835 件2026 年: 被引用 10 件1991〜1993 年は被引用が無いため表示していません1995 年は被引用が無いため表示していません1997 年は被引用が無いため表示していません1999 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,209 件、この内訳の 20.2%ドイツ: 引用元論文 1,151 件、この内訳の 7.3%フランス: 引用元論文 1,064 件、この内訳の 6.7%イギリス: 引用元論文 932 件、この内訳の 5.9%イタリア: 引用元論文 895 件、この内訳の 5.6%中国: 引用元論文 746 件、この内訳の 4.7%スペイン: 引用元論文 744 件、この内訳の 4.7%オランダ: 引用元論文 722 件、この内訳の 4.5%ベルギー: 引用元論文 476 件、この内訳の 3%スイス: 引用元論文 453 件、この内訳の 2.9%オーストラリア: 引用元論文 424 件、この内訳の 2.7%カナダ: 引用元論文 393 件、この内訳の 2.5%
0%20.2%その他 29.3%

分野

  • Medicine88.4%
  • Biochemistry, Genetics and Molecular Biology5.4%
  • Immunology and Microbiology3.4%
  • Agricultural and Biological Sciences0.6%
  • Pharmacology, Toxicology and Pharmaceutics0.4%
  • Engineering0.3%
  • その他1.5%

トピック

  • Antifungal resistance and susceptibility14.3%
  • Fungal Infections and Studies10.4%
  • Acute Myeloid Leukemia Research5.5%
  • Hematopoietic Stem Cell Transplantation4.4%
  • Neutropenia and Cancer Infections3%
  • Cytomegalovirus and herpesvirus research2.8%
  • その他59.6%

共著者

全論文

検索で開く
  1. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christopher C. Kibbler, Dimitrios P. Kontoyiannis, Bart Jan Kullberg, Katrien Lagrou, Frédéric Lamoth, Thomas Lehrnbecher, Jürgen Loeffler, Olivier Lortholary, Johan Maertens, Oscar Marchetti, Kieren A. Marr, Henry Masur, Jacques F. Meis, C Orla Morrisey, Márcio Nucci, Luis Ostrosky‐Zeichner, Livio Pagano, Thomas F. Patterson, John R. Perfect, Zdeněk Ráčil, Emmanuel Roilides, Marcus Ruhnke, Cornelia Schaefer Prokop, Shmuel Shoham, Monica A. Slavin, David A. Stevens, George R. Thompson, José A. Vázquez, Claudio Viscoli, Thomas J. Walsh, Adilia Warris, L. Joseph Wheat, P. Lewis White, Theoklis E. Zaoutis, Peter G. Pappas - Clinical Infectious Diseases 2019 被引用: 2,817

  2. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Claus Peter Heußel, C Kibbler, Н Н Климко, Bart Jan Kullberg, Christoph Lange, Thomas Lehrnbecher, Jürgen Löffler, Olivier Lortholary, Johan Maertens, Oscar Marchetti, Jacques F. Meis, Livio Pagano, Patricia Ribaud, Malcolm Richardson, Emmanuel Roilides, Markus Ruhnke, Maurizio Sanguinetti, Donald C. Sheppard, János Sinkó, Anna Skiada, Maria J. G. T. Vehreschild, Claudio Viscoli, Oliver A. Cornely - Clinical Microbiology and Infection 2018 被引用: 1,518

  3. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

    著者: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 被引用: 1,206

  4. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Theoklis E. Zaoutis, John E. Bennett - Clinical Infectious Diseases 2008 被引用: 4,909

  5. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2015 被引用: 972

  6. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial

    著者: , , , , , , , , , , , , , , , , , , - Clinical Infectious Diseases 2021 被引用: 300

  7. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

    著者: , , , , , , , , , , , , , , , , , , , - Blood 2022 被引用: 290

  8. Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia

    著者: , , , , , , , , , , , , , - New England Journal of Medicine 2007 被引用: 1,807

  9. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial

    著者: , , , , , , , , , , , , , , , , , - The Lancet 2021 被引用: 276

  10. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Intensive Care Medicine 2020 被引用: 454

  11. CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2018 被引用: 205

  12. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Carolyn Sasse, Rochelle Maher, Bernhardt Zeiher, Maria J. G. T. Vehreschild - The Lancet Infectious Diseases 2016 被引用: 694

  13. Combination Antifungal Therapy for Invasive Aspergillosis

    著者: , , , , , , , , , , , , , , , , , , - Annals of Internal Medicine 2015 被引用: 500

  14. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia

    著者: , , , , , , , , , , , , - Journal of Antimicrobial Chemotherapy 2018 被引用: 339

  15. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European Confederation of Medical Mycology

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marina Linhofer, Jonas Frost, Peter Zechner, Matthias Kochanek, Philipp Eller, Jeffrey D. Jenks, Sara Volpi, Anne‐Pauline Bellanger, P. Lewis White, Gustavo H. Goldman, Paul Bowyer, Antonis Rokas, Sara Gago, Paolo Pelosi, Chiara Robba, Jean‐Pierre Gangneux, Cornelia Lass-Floerl, Marina Machado, Patricia Muñóz - Clinical Microbiology and Infection 2021 被引用: 230

  16. Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , José A. Vázquez, Joost Wauters, Erika Asperges, Andrea Cortegiani, Cecilia Grecchi, Ilias Karaiskos, Clément Le Bihan, Toine Mercier, Klaus Leth Mortensen, Maddalena Peghin, Chiara Rebuffi, Sofía Tejada, Antonio Vena, Valentina Zuccaro, Luigia Scudeller, Thierry Calandra, Claire Roger, Christian Eckmann, Jean‐Pierre Gangneux, Esther Segal, Geoffrey W. Coombs, Andreas Voß - Intensive Care Medicine 2024 被引用: 171

  17. High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

    著者: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2009 被引用: 822

  18. High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jennita Slomp, Alexander N. Snel, Marie‐Christiane Vekemans, Bob Löwenberg, Gert J. Ossenkoppele, Gerrit Jan Schuurhuis - Journal of Clinical Oncology 2013 被引用: 449

  19. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2009 被引用: 719

  20. ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients

    著者: , , , , , , , , , , , , - Journal of Antimicrobial Chemotherapy 2016 被引用: 409

  21. Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Infectious Diseases 2008 被引用: 460

  22. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients

    著者: , , , , , , , , , , , , - Journal of Antimicrobial Chemotherapy 2016 被引用: 295

  23. Antifungal drugs: What brings the future?

    著者: , , , , , , - Medical Mycology 2019 被引用: 219

  24. Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation

    著者: , , , , , , , , , - New England Journal of Medicine 2019 被引用: 181